Open AccessTherapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy
Author(s) -
Monica Bocchia,
Angelo Michele Carella,
Antonino Mulè,
Lorenzo Rizzo,
Mauro Turrini,
Maria Chiara Abbenante,
Roberto Cairoli,
Valeria Calafiore,
Marzia Defina,
Angelo Gardellini,
Giovanni Luzi,
Caterina Patti,
Maria Beatrice Pinazzi,
Marta Riva,
Giovanni Rossi,
Vincenzo Sammartano,
Luigi Rigacci
Publication year - 2022
Publication title -
pharmacogenomics and personalized medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 28
ISSN - 1178-7066
DOI - 10.2147/pgpm.s346688
Subject(s) - medicine , myeloid leukemia , midostaurin , tyrosine kinase inhibitor , myeloid , acute leukemia , leukemia , concomitant , tyrosine kinase , cancer research , bone marrow , cancer , receptor
Acute myeloid leukemia is a malignant disorder of the bone marrow, characterized by differentiation, clonal expansion, and uncontrolled proliferation of malignant myeloid progenitor cells and by several molecular and genetic abnormalities. A mutation of FMS-like tyrosine kinase 3 gene can be observed in about one-third of cases of acute myeloid leukemia. Two FLT3 inhibitors are actually approved for FLT3 mutated acute myeloid leukemia: midostaurin, a multikinase first generation inhibitor with lower affinity for FLT3 binding, and gilteritinib fumarate, a potent second-generation inhibitor of both FLT3-ITD and TKD. Gilteritinib is a new effective and well-tolerated drug for patients with relapsing or refractory FLT3-positive acute myeloid leukemia. Thanks to its efficacy, low toxicity, its good manageability (oral formulation), this drug is suitable for all the patients, including elderly frail patient with concomitant therapies or pre-existing or underlying diseases, and can be used also in the outpatient setting, reducing risks and costs related to the hospitalization. We report and discuss seven cases of different patients with FLT3 positive acute myeloid leukemia successfully managed with gilteritinib in the real clinical practice.